Skip to main content
. 2013 Aug 22;280(21):5269–5282. doi: 10.1111/febs.12453

Figure 6.

Figure 6

Loss of STAT3 function decreases neuroblastoma cell proliferation. (A, B) Neuroblastoma cell lines CLB-GE (▪), CLB-BAR (▴), Kelly (‐) and CLB-GA (•) were treated with 250 nm crizotinib (A) and 1.5 μm FLLL32 (B) for 5 days. Proliferation was analyzed with the resazurin cell proliferation assay. Values are reported as fold relative fluorescence from FLLL32-treated cells versus relative fluorescence from untreated cells (♦). Results are from three representative experiments, with each experiment performed in triplicate. (C) Neuroblastoma cell lines CLB-BAR, CLB-GE, CLB-GA and Kelly were grown on six-well plates with complete growth medium, starved, and treated with 250 nm crizotinib and 1.5 μm FLLL32 for 6 h. Cell lysates were immunoblotted with antibodies against p-STAT3 and PARP. Tubulin was used as a loading control. (D–G) CLB-BAR (D), CLB-GA (E) CLB-GE (F) and Kelly (G) cell lines were transfected with scrambled siRNA (SiC) (▪), STAT3 siRNA#1 (Si1) (▴) or STAT3 siRNA#2 (Si2) (▴) at 0 and 24 h. Cell viability was assessed at 0, 3, 4 and 5 days post-transfection, with the resazurin assay. Values are reported as fold relative fluorescence from siRNA-transfected cells versus relative fluorescence from control mock-transfected cells. Results are from one of three representative experiments, with each experiment performed in triplicate.